Articles tagged "Rejection"

2022 American Transplant Congress
Impact of the Covid-19 Pandemic on Longitudinal Molecular Surveillance in the KOAR Registry
T. Alhamad¹, A. Malone¹, D. Mandelbrot², P. M. Anand³, H. M. Wadei⁴, G. Shekhtman⁵, N. Agrawal⁵, K. Pinney⁵, K. Qu⁵, A. Desai⁶
¹Washington University, St. Louis, MO, ²University of Wisconsin, Madison, WI, ³Medical University of South Carolina, Charleston, SC, ⁴Mayo Clinic Jacksonville, Jacksonville, FL, ⁵CareDx, Brisbane, CA, ⁶Loyola University Medical Center, Maywood, IL
*Purpose: The SARS-CoV2 pandemic increased the complexity of delivering routine clinical care and laboratory services for immunosuppressed kidney transplant (KTx) recipients. We evaluated how the…
2022 American Transplant Congress
The Effect of Tacrolimus and Mycophenolic Acid on Torque Teno Virus Loads in Kidney Transplant Recipients
A. van Rijn, S. Meziyerh, D. van der Helm, T. van Gelder, A. Kroes, J. de Fijter, D. Moes, J. Rotmans, A. de Vries, M. Feltkamp
Leiden University Medical Center, Leiden, Netherlands
*Purpose: Measuring immune function in kidney transplant recipients (KTRs) remains challenging given the precarious balance between over- and underimmunosuppression. This is primarily due to high…
2022 American Transplant Congress
De Novo Focal Segmental Glomerulosclerosis in the Kidney Allograft: Association with Alloimmunity Leading to Poor Outcome
J. Leon¹, J. Duong Van Huyen², A. Abderrahmane¹, D. Anglicheau¹, C. Legendre¹, M. Rabant²
¹KIDNEY TRANSPLANTATION, Necker Hospital, Paris, France, ²KIDNEY PATHOLOGY, Necker Hospital, Paris, France
*Purpose: Focal Segmental Glomerulosclerosis (FSGS) can be found de novo (Dn) or as a recurrence in kidney allograft. While FSGS recurrence has been extensively described…
2022 American Transplant Congress
Immunosuppressant Medications Use in Patients with Transplant Failure: A Canadian Multi-Centre Prospective Study
G. Knoll¹, M. Chassé², D. Fergusson³, A. A. House⁴, O. Johnston⁵, R. Mainra⁶, D. Baran⁷, D. Treleaven⁸, l. senecal⁹, L. Tibbles¹⁰, M. Hebert¹¹, M. Karpinski¹², T. Campbell¹³, T. Ramsay¹⁴, J. Kim¹⁵, I. Houde¹⁶, C. White¹⁷, J. Perl¹⁵, P. Karnabi¹⁸, J. Gill⁵
¹Nephrology, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ²University of Montreal, Montreal, QC, Canada, ³Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁴Nephrology, Western University, London, ON, Canada, ⁵Nephrology, University of British Columbia, Vancouver, BC, Canada, ⁶Nephrology, University of Saskatchewan, Saskatoon, SK, Canada, ⁷Nephrology, McGill University, Montreal, QC, Canada, ⁸Nephrology, McMaster University, Hamilton, ON, Canada, ⁹Nephrology, Maisonneuve-Rosemont Hospital, Montreal, QC, Canada, ¹⁰Nephrology, University of Calgary, Calgary, AB, Canada, ¹¹Nephrology, University of Montreal, Montreal, QC, Canada, ¹²Nephrology, University of Manitoba, Winnipeg, MB, Canada, ¹³University of Alberta, Alberta, AB, Canada, ¹⁴Ottawa Hospital Research Institute, Ottawa, ON, Canada, ¹⁵University of Toronto, Toronto, ON, Canada, ¹⁶Laval University, Que´bec, QC, Canada, ¹⁷Queen's University, Kingston, ON, Canada, ¹⁸Ottawa Health Research Institute, Ottawa, ON, Canada
*Purpose: This prospective study determined the association of immunosuppressant medication use with the outcomes of death, hospitalized infection, rejection of the failed allograft, and panel…
2022 American Transplant Congress
Outcomes of a Standardized Antibody-Mediated Rejection (AMR) Treatment Protocol in Heart Transplant Recipients (HTR)
J. Lee, T. Sam, J. Van Zyl, S. Mckean, L. Fuller, N. Wilson, A. Dao, R. Gottlieb, S. Hall, R. Patel
Baylor University Medical Center, Dallas, TX
*Purpose: AMR in HTR portends poor clinical outcomes. Reported mortality range between 20-50%, with higher rates reported for late AMR occurring at least 1 year…
2022 American Transplant Congress
Study of the Composition of the Inflammatory Burden on a Cohort of 125 Rejections by Multiplex Immunofluorescence
A. Mobio¹, M. Eloudzeri², L. Morin¹, J. Duong Van Huyen³, D. Anglicheau¹, M. Rabant³
¹Kidney transplantation, Necker-Enfants Malades Hospital, Paris, France, ²U1151, INEM, Paris, France, ³Pathology, Necker-Enfants Malades Hospital, Paris, France
*Purpose: The exact composition of the inflammatory burden during kidney transplant rejection has not been studied on large cohorts. Moreover, the determinants and impact of…
2022 American Transplant Congress
The Use of Donor-Derived Cell-Free DNA in Female and Male Heart Transplant Recipients: A Sex-Specific Analysis of the Surveillance Heartcare Outcomes Registry
E. M. DeFilippis¹, Y. Fu², R. Burke², M. Deng³, M. Kamath⁴, L. Lourenco Jenkins², A. R. Vest⁵
¹Columbia University Irving Medical Center, New York, NY, ²CareDx, Brisbane, CA, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁵Tufts Medical Center, Boston, MA
*Purpose: To investigate sex-specific donor-derived cell-free DNA AlloSure (AS) levels during allograft quiescence and rejection after heart transplantation.*Methods: Sex-stratified data were obtained from the Surveillance…
2022 American Transplant Congress
TCMR in Late Kidney Transplant Biopsies Shows Less Molecular TCMR Activity and More Fibrosis Despite Persistence of Tubulitis and Interstitial Infiltrate
K. S. Madill-Thomsen¹, J. Reeve¹, P. Halloran¹, .. and the INTERCOMEX Study Group²
¹Alberta Transplant Applied Genomics Centre, Edmonton AB, AB, Canada, ²., ., AB, Canada
*Purpose: We studied the relationship between time post-transplant and molecular T cell-mediated rejection (TCMR) activity in a population of indication kidney transplant biopsies.*Methods: Updated rejection-based…
2022 American Transplant Congress
Noninvasive Biomarkers for Allograft Monitoring After Intestinal Transplantation: Promising Early Results from a Novel Peptide, REG3α
C. P. Smullin¹, R. S. Venick², E. A. Marcus², B. V. Naini³, D. G. Farmer⁴
¹David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ²Pediatrics, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ³Pathology, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, ⁴Surgery, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA
*Purpose: There is an urgent need for the discovery and application of noninvasive biomarkers to detect allograft rejection after intestinal transplantation (ITx). Calprotectin and citrulline…
2022 American Transplant Congress
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
¹Nephrology, University of Washington, Seattle, WA, ²Surgery, University of Washington, Seattle, WA, ³Bloodworks Northwest, Seattle, WA
*Purpose: The optimal treatment for chronic active antibody-mediated rejection (ca-AMR) remains unclear. Tocilizumab (TCZ), a monoclonal antibody against IL-6, has been proposed in ca-AMR treatment…

« Previous Page
1
…
3
4
5
6
7
…
172
Next Page »